Search For "controller"
Zydus gets Mexican regulator nod to conduct clinical trials with Pegylated
Updated : 5 years, 8 months ago IST
Ahmedabad (Gujarat) [India], July 17 (ANI): Pharmaceutical major Zydus said on Friday it has got approval from Mexico's Federal Commission for the Protection against Sanitary Risk (COFEPRIS) to conduct clinical trials with its biological therapy 'Pegylated Interferon alpha-2b' for the treatm
Read More
Pharma giant Zydus Cadila initiates clinical study on 1,048 volunteers for
Updated : 5 years, 8 months ago IST
New Delhi [India], July 15 (ANI): Indian pharmaceutical giant Zydus Cadila has initiated the phase 1, 2 clinical trial to evaluate the safety and immunogenicity of coronavirus vaccine candidate by intradermal (injection) route in 1,048 subjects after the pharma company got approval from D
Read More
DCGI gives market approval for Pneumococcal Polysaccharide Conjugate Vacci
Updated : 5 years, 8 months ago IST
New Delhi [India], July 15 (ANI): The Drug Controller General of India (DCGI) has given approval to the first fully indigenously developed Pneumococcal Polysaccharide Conjugate Vaccine.
Read More
Biocon's drug Itolizumab gets DCGI nod for use in moderate to severe Covid
Updated : 5 years, 8 months ago IST
Bengaluru (Karnataka) [India], July 11 (ANI): Biopharmaceutical major Biocon Ltd said on Saturday it has received approval from the Drugs Controller General of India (DCGI) to market Itolizumab injection 25mg/5ml solution for emergency use in India for the treatment of cytokine release syndr
Read More
DCGI approves Itolizumab injection for restricted emergency use on COVID-1
Updated : 5 years, 8 months ago IST
New Delhi [India], July 11 (ANI): The Drug Controller General of India (DCGI) granted its permission to Itolizumab injection for the restricted emergency use on COVID-19 patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS) due to virus.
Read More
DCGI instructs pharma giants manufacturing remdesivir to upload details of
Updated : 5 years, 8 months ago IST
New Delhi [India], July 9 (ANI): Witnessing the incidence of black marketing and overcharging of the remdesivir injection above MRP, the Drugs Controller General of India (DCGI) has directed all three pharma giants--Cipla, Hetero, and Mylan to upload the details of anti-viral Remedsivir drug
Read More
COVID19: Top drug regulator directs states drug controller to be vigilant
Updated : 5 years, 8 months ago IST
New Delhi [India], July 7 (ANI): The country's top drug regulator has directed all drug controller in the States and Union Territories to keep strict vigil to prevent the black marketing and sale of the anti-drug Remdesivir injection above the minimum retail price (MRP).
Read More
Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per via
Updated : 5 years, 8 months ago IST
Bengaluru (Karnataka) [India], July 7 (ANI): Global pharmaceutical major Mylan has got approval for its remdesivir from the Drug Controller General of India (DCGI) and will launch a generic version of Gilead Sciences' COVID-19 anti-viral in the country at Rs 4,800 for 100 mg/vial.
Read More
DCGI permits human clinical trials for COVID-19 vaccine of Zydus Cadila
Updated : 5 years, 8 months ago IST
New Delhi [India], July 3 (ANI): The Drug Controller General of India (DCGI) on Thursday granted permission to pharma giant Zydus Cadila to conduct phase I and phase II human clinical trials for COVID -19 vaccine, a top government official told ANI.
Read More
DCGI gives nod to Mylan labs to manufacture remdesivir for 'restricted eme
Updated : 5 years, 8 months ago IST
New Delhi [India], July 2 (ANI): The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for 'restricted emergency use' on hospitalised COVID-19 patients, a senior government official said on Thursday.
Read More
DCGI gives nod to Bharat Biotech to conduct phase I & II Human clinica
Updated : 5 years, 8 months ago IST
New Delhi [India], June 30 (ANI): The Drug Controller General of India (DCGI) has granted permission to Bharat Biotech International Limited (BBIL) to conduct Phase I and II Human clinical trials to develop an indigenous vaccine for COVID-19 -- in the name COVAXIN.
Read More
Glenmark, Cipla stocks surge after nod to launch drugs for mild-to-moderat
Updated : 5 years, 8 months ago IST
Mumbai (Maharashtra) [India], June 22 (ANI): Glenmark Pharmaceuticals' share price surged 30 per cent on Monday to Rs 531.80 per unit after it became the first pharmaceutical company in India to receive regulatory approval to make and sell oral antiviral drug favipiravir for treating mild-to
Read More